Document Detail

When to measure lipid profile after stroke?
MedLine Citation:
PMID:  15731554     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Although acute decreases in total cholesterol (TC) are well documented in myocardial infarction, previous stroke studies have produced conflicting results. The timing of lipid estimation in ischemic stroke is becoming important with recent trial results indicating the benefits of statins. We therefore aimed to determine the optimal time for lipid measurements after stroke. We hypothesized that TC would acutely decrease after stroke and return to baseline by 12 weeks. METHODS AND RESULTS: We performed a prospective, observational study of 50 patients (age 68.5 +/- 11.2 years) who presented with acute ischemic stroke. Of these, 22 (44%) were HMG-CoA reductase (statin) naïve, 15 (30%) had already been on statins and 13 (26%) were commenced on statins. Of the 50 patients, 38 (76%) completed 12 weeks of follow-up, 5 died, and 7 were lost to follow-up. Fasting lipid profile (TC, low-density lipoprotein, high-density lipoprotein, triglyceride) was measured <48 h, 4 weeks and 12 weeks following ictus. In patients who were statin naïve, there was a significant increase in TC at the week 12 evaluation. CONCLUSIONS: Cholesterol levels in acute stroke are an unreliable measure of lipid status. Initiation of statins should ideally be based on measurements taken 12 weeks after stroke.
Bernard Yan; Mark Parsons; Sharyn McKay; Donald Campbell; Bernard Infeld; Raymond Czajko; Stephen M Davis
Related Documents :
6133104 - Belgian heart disease prevention project: incidence and mortality results.
11965214 - Chemoprevention of coronary atherosclerosis: the role of lipid interventions. a positio...
11861414 - Loss of sr-bi expression leads to the early onset of occlusive atherosclerotic coronary...
7465464 - Dietary prevention at home and abroad.
20686414 - Cardiovascular magnetic resonance of acute myocardial infarction following traumatic co...
12213494 - Alterations of sarcolemmal phospholipase d and phosphatidate phosphohydrolase in conges...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-02-22
Journal Detail:
Title:  Cerebrovascular diseases (Basel, Switzerland)     Volume:  19     ISSN:  1015-9770     ISO Abbreviation:  Cerebrovasc. Dis.     Publication Date:  2005  
Date Detail:
Created Date:  2005-04-08     Completed Date:  2005-06-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9100851     Medline TA:  Cerebrovasc Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  234-8     Citation Subset:  IM    
Copyright Information:
Copyright 2005 S. Karger AG, Basel.
Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Anticholesteremic Agents / therapeutic use
Chemistry, Clinical / standards*
Cholesterol / blood*
Follow-Up Studies
Hyperlipidemias / blood,  drug therapy
Middle Aged
Prospective Studies
Reproducibility of Results
Stroke / blood*
Time Factors
Reg. No./Substance:
0/Anticholesteremic Agents; 57-88-5/Cholesterol
Comment In:
Cerebrovasc Dis. 2005;20(3):211   [PMID:  16103647 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Severe umbilical cord acidemia and neurological outcome in preterm and full-term neonates.
Next Document:  Neurotrophic factor expression after focal brain ischemia preceded by different preconditioning stra...